Feasibility of arresting the process of remodeling.
Heart failure (HF) is a massive public health issue. Ventricular remodeling is pivotal to the pathophysiology/progression of HF and an attractive target for intervention. It currently is believed that interdicting the natural history of ventricular remodeling will be crucial to controlling the HF epidemic. This article reviews the current data on the feasibility of arresting this process. This review is not meant to be exhaustive but provides a brief overview of the approaches being contemplated in this field.
University of Minnesota, Minneapolis, MN 55417, USA.
P E
PE
Somasundaram
Y
Y
Chandrashekhar
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002304:Cardiac Pacing, Artificial; D018421:Cardiomyoplasty; D002316:Cardiotonic Agents / Q000627:therapeutic use; D018450:Disease Progression; D005240:Feasibility Studies; D006333:Heart Failure / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000517:prevention & control*; D006353:Heart-Assist Devices; D006801:Humans; D018579:Patient Selection; D010686:Philosophy, Medical; D011237:Predictive Value of Tests; D012307:Risk Factors; D016879:Salvage Therapy / Q000379:methods; D016019:Survival Analysis; D016896:Treatment Outcome; D020257:Ventricular Remodeling / Q000187:drug effects / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents